Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
about
Intravenous immunoglobulins for the treatment of infections in patients with haematological cancersPrimary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsIntravenous immunoglobulins for the treatment of infections in patients with haematological cancersColony-stimulating factors for the prevention of chemotherapy induced febrile neutropenia in breast cancer patientsChinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patientsChinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patientsSerpinB1 protects the mature neutrophil reserve in the bone marrowMedical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activitiesPharmacodynamic modeling of adverse effects of anti-cancer drug treatmentLipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patientsHow Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future DirectionsA novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cellsXRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in MiceOptofluidic device for label-free cell classification from whole blood.Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.Solitary plasmacytoma of the jawAdverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expressionRare bacterial isolates causing bloodstream infections in Ethiopian patients with cancerHodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.Fat composition changes in bone marrow during chemotherapy and radiation therapy.Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens?Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropeniaOutpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemiaThe management of acute adverse effects of breast cancer treatment in general practice: a video-vignette study.Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOPPegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)Incidence of hospital-acquired pneumonia, bacteraemia and urinary tract infections in patients with haematological malignancies, 2004-2010: a surveillance-based studyA prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findingsOverview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Febrile neutropenia in hematologic malignancies.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV.Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumoursUptake of novel medical therapies in the general population.Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centresStudy design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay.
P2860
Q24186274-15272AE0-8DF9-49CA-B269-66A4A0D670DAQ24198118-F42D7C49-A0BC-45C6-8B6B-7B6DEE4E0018Q24236448-33442EBD-3AA2-41AB-ABC5-0626A30CD7EBQ24240768-F9707BDA-905D-49F7-ADEE-B6F92F7E483BQ24245485-375C3072-781A-4A6D-B072-649646ADC5C1Q24246914-BB1E25C3-741B-41F6-B96E-0A43ED7B29ADQ24614199-BDF00493-07A0-4E15-8083-11CC6F66CF51Q24791224-A96B0043-2B07-4E42-9D59-853CBE8AAAAEQ26766318-A89E9E91-EA15-4A70-A58D-A6B525006004Q26768126-EAB7D377-17E8-4749-AE6B-A2778C135A7DQ26771113-D9D6E492-2F7F-4519-A909-8A22B5E5B8B2Q27302772-55D8BCBB-F56A-4562-909A-81E5F2BA022CQ27333970-A6FEC57B-1177-473F-916F-971E5FA1C399Q30448465-67332F58-FB5A-47B8-B62E-0D15CBAD2BA7Q30975418-030803B0-9C09-4B7F-A89E-D7FF5C6CD680Q33389472-82E13532-638F-45BD-AB04-24805337B595Q33399368-EC64BF6D-5C12-4E7D-A1CF-21A0CA8E0C86Q33410375-A6FB3C5B-37E4-4D78-A4B5-12A7598B7BDEQ33599892-5F454392-815E-4580-B579-2DDCBC4DD1A1Q33695077-ED23D61A-2CF9-46FA-ABA3-3242FF43D337Q33892651-7110D9E4-0701-4B7F-9636-B17131A23F90Q34104990-2BB4DA45-EC18-4378-954E-03A75D560CA6Q34156572-F9BFA39C-6C53-43C8-B2D0-5E0DD1E55A30Q34229622-49FDF32A-9E60-40BF-8CB2-9BD854211411Q34403621-4380C5DB-32EB-4DFA-9814-73FE83B8CAB7Q34418965-59488349-7402-43F7-974A-C45F0A28C8A1Q34424508-22D93C82-6CA4-4D58-91B8-6E6BD2A7C91AQ34528537-F876EE14-FD98-4F29-B0C6-D228E8C6FE52Q34539360-7D15FF16-7A37-4593-8088-811694124AA0Q34614712-042F7EC9-737D-4696-A97A-3D510E0A1D8EQ34627796-274F614E-7080-41B7-A9AD-FA00983A09C7Q34635638-CD6D0947-C671-4CE1-91A5-BF79048B7D61Q34655730-704A4EC7-667A-436B-8A15-5270866BF216Q34670717-1ED00FA2-61CE-4E2F-A8A4-0C77511BF568Q34746166-07F619E1-5EA7-4615-A057-8B219E320056Q34858123-9EF84BDE-E244-42EE-9FEC-5BB020322DE6Q35026985-7F57ED00-B7FE-481A-AFF5-81C00EFDA84CQ35026994-3D292015-4FDB-4BF1-87BB-454E98C5B714Q35044368-C39FF72F-8906-4541-B23D-0528449B83F7Q35054865-60094E5B-10E1-41D2-AD7E-E7AD626E0542
P2860
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Chemotherapy-induced neutropen ...... directions for its management.
@ast
Chemotherapy-induced neutropen ...... directions for its management.
@en
type
label
Chemotherapy-induced neutropen ...... directions for its management.
@ast
Chemotherapy-induced neutropen ...... directions for its management.
@en
prefLabel
Chemotherapy-induced neutropen ...... directions for its management.
@ast
Chemotherapy-induced neutropen ...... directions for its management.
@en
P2093
P356
P1433
P1476
Chemotherapy-induced neutropen ...... directions for its management.
@en
P2093
David C Dale
Gary H Lyman
Jeffrey Crawford
P304
P356
10.1002/CNCR.11882
P407
P577
2004-01-01T00:00:00Z